BioSpace News Archive

QDx Pathology Services, an independent anatomical, molecular, and clinical pathology laboratory serving medical professionals and facilities throughout the United States

Cell MedX Corp. (OTC Pink: CMXC) (“Cell MedX”, or the “Company”) a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report fourth quarter and year-end 2023 financial results on Tuesday, March 26, 2024.

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced fourth quarter and full year 2023 financial results and provided a business update.

XOMA Corporation entered into a merger agreement to acquire Kinnate Biopharma Inc. for a base cash price per share of Kinnate common stock of $2.3352 per share and an additional cash amount of not more than $0.2527 per share.

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Bloom Burton Healthcare Conference on Tuesday, April 16, 2024, at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time).

BioAtla, Inc. today announced that it plans to host a conference call and webcast on Tuesday, March 26, 2024 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full-year ended December 31, 2023 and provide business highlights.

Alimera Sciences, Inc. announces that the first patient has been randomized in the DRCR Retina Network’s Protocol AL. The study is titled, “A Randomized Clinical Trial Evaluating Intravitreal Faricimab (6.0 mg) Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of Visual Acuity Loss due to Radiation Retinopathy.”

Nuvectis Pharma, Inc. today announced upcoming presentations for NXP800 and NXP900 at the upcoming 2024 American Association for Cancer Research Meeting (2024 AACR), taking place from April 5th to April 10th in San Diego, Ca.

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study of optical genome mapping (OGM) in hereditary breast and ovarian cancer (HBOC) syndrome showing that when tumors exhibited higher overall numbers of structural variations (SVs) they tended to have more mutated genes and altered signaling pathways, which may correlate with poor prognosis, tumor progression and chemotherapy resistance.